Richard

Business Development Executive @CGTCatapult Ex Fellow @Lborouniversity and @UniofNottingham. #CellTherapy and #AdvancedTherapies manufacturing. Views are my own

[Richard @DrRichPHarrison]

@CGTCatapult brings together over 20 organisations with the aim to accelerate technology development and potentially lower cost in cell and gene therapy. The organisations forming the consortium are: @AberInstruments @AnthonyNolan @BDandCo @biotechne @CambConsultants @CITSensMeMo

[Richard @DrRichPHarrison]

Excited to see our Process Analytical Technology Consortium was announced today. This was a huge amount of work, but I am so excited to see the results we can create together. #PATConsortium #manufacturing. Get the full story: https://t.co/xNpGSKLRmF

[Richard @DrRichPHarrison]

@3rdfloorlab Get the veggies in Eric

[Aileen Gracias @gracias_aileen]

Innovation and research commercialization insights from CSPC2019 @sciencepolicy https://t.co/kSDTlTwpwA #cspc2019 @CCRM_ca

[Sven Kili @Biosurgerysven]

UK government boosts expansion of cell therapy in the NHS with new standardization program. Hopefully it will be suitable for global use so that companies are able to use this system more widely. https://t.co/F0kY3UsuQk #regenmed

[Richard @DrRichPHarrison]

How Canadian cell and gene therapy companies can grow in the UK
https://t.co/PtL25BhVl2

[Sven Kili @Biosurgerysven]

Brexit who? Record investment last year fuels big spike in registered UK biotech firms - https://t.co/OLDARVdfgt

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Better than a fidget spinner

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

https://t.co/AGE3NAYptW

[Christian Chabannon @CChabannon]

Another application for CAR-T Cells, beyond oncology! Genetically engineered immune cells wipe out lupus in mice https://t.co/gB7cVFHNiL

[Richard @DrRichPHarrison]

A shame to see Scott go, his record of sensible and measured decisions for #advancedtherapies was exactly what the sector needed. https://t.co/fW8ZQ4gi2e

[Richard @DrRichPHarrison]

Pleased to see this research on process cost of goods for neutrophil #celltherapy out in Frontiers.

[CCRM @CCRM_ca]

Congrats @lizcsaszar @DrRichPHarrison et al on your new publication: Ex vivo Manufactured Neutrophils for Treatment of Neutropenia—A Process Economic Evaluation https://t.co/DGlPPxWXNz

[Institute for Bioengineering and Bioscience @ GT @ibbgatech]

Our exec director, Andrés García, presenting to NSF at the @CMaT_ERC annual site visit. @GarciaLabGT & @WilburLam lead CMaT’s thrust 2 working to engineer reproducible, predictive measurement & assay technologies enabling batch & continuous monitoring of cell state & product.

[Paul Knoepfler @pknoepfler]

Yikes! @nature published un-peer-reviewed "article" that was actually a paid advertisement for controversial (maybe non-existent?) kind of #stemcells. Kudos to them for opting to quickly remove it https://t.co/jShrdahBJ6 #stemcell #bioethics

[Comprehensive Cell Solutions,New York Blood Center @CcsNybc]

Article written in the journal of cell therapy...@CcsNybc can play a large role in reducing manufacturing COGs.

https://t.co/mTThuunacv

[Nature Biotechnology @NatureBiotech]

In the first of a three-part series on science start-ups, @NatureCareers explores how scientists with a sound business idea can thrive as entrepreneurs, and why leaving academia isn’t required https://t.co/ouFgy7dlGf

[Bertrand Delsuc @BertrandBio]

modelling COGs auto vs allo CAR-Ts: ~100k$ vs <5k$ est. (in line w/ $CLLS disclosures for allo)

Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods - by @BLLPHD et al. #openaccess
https://t.co/rWcDOeWnNU

[Richard @DrRichPHarrison]

Really pleased to see our work out out @BLLPHD and @Simon_H_Ellison although I have to say this work came from @lborouniversity and @UoNresearch

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods w/Richard Harrison @CGTCatapult Ezequiel Zylberberg @AkronBiotech Simon Ellison @Worldcourier
https://t.co/PE8evjWass

[Nature Portfolio @NaturePortfolio]

A new enzyme (called CasX) able to manipulate the human genome is shown to provide different editing functionality than previously described CRISPR–Cas platforms. This finding, reported in Nature, adds another tool to the CRISPR toolkit. https://t.co/TbaA9wfrib